Expert Opinion on Drug Delivery

Publisher: Informa Healthcare

Current impact factor: 4.84

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 4.84
2013 Impact Factor 4.116
2012 Impact Factor 4.869
2011 Impact Factor 4.896
2010 Impact Factor 4.482
2009 Impact Factor 3.345

Impact factor over time

Impact factor

Additional details

5-year impact 5.02
Cited half-life 4.40
Immediacy index 1.05
Eigenfactor 0.01
Article influence 1.16
ISSN 1744-7593

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • Non-commercial
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification

Publications in this journal

  • Jooho Park · Youngro Byun ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Anticoagulants have been prescribed to patients to prevent deep vein thrombosis or pulmonary embolism. However, because of several problems in anticoagulant therapy, much attention has been directed at developing an ideal anticoagulant, and numerous attempts have been made to develop new anticoagulant delivery systems in recent years. Areas covered: This review discusses the challenges associated with the recent development of anticoagulants and their delivery systems. Various delivery methods have been developed to improve the use of anticoagulants. Recent advances in anticoagulant delivery and antidote development are also discussed in the context of their current progression states. Expert opinion: There have been many different approaches to developing the delivery system of anticoagulants. One approach has been to expand the use of new oral agents and develop their antidotes. Reducing the size of heparins to use smaller heparins for delivery, and developing oral or topical heparins are also some of the approaches taken. Various physical formulations or chemical modifications are other ways that have enhanced the therapeutic potential of anticoagulant agents. On the whole, recent advances have contributed to increasing the efficacy and safety of anticoagulant clinically and have benefited the field of anticoagulant delivery.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1125880
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Dosing regimens requiring multiple daily applications frequently result in poor patient compliance, especially in the treatment of chronic skin diseases. Consequently, development of sustained delivery systems for topical drugs permitting less frequent dosing is of continuing interest for dermatological therapy. Areas covered: This potential of polymeric film-forming systems (FFS), created in situ on the skin, as sustained delivery platforms for topical drug delivery is reviewed. Key formulation parameters that determine delivery efficiency are considered focussing on those that permit a drug reservoir to be established in the upper layers of the skin and/or on the skin surface from which release can be sustained over a prolonged period. The advantageous and superior cosmetic attributes of FFS (compared to conventional semi-solid formulations) that offer significantly improved patient compliance are also addressed. Expert opinion: The promise of polymeric FFS as convenient and aesthetic platforms for sustained topical drug delivery is clear. Manipulation of the formulation allows the delivery profile to be customised and optimised to take advantage of both a rapid, initial input of drug into the skin (likely due to a transient period of supersaturation) and a slower, controlled release over an extended time from the residual film created thereafter.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1124412
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To develop and characterize a highly respirable dry powder inhalable formulation of voriconazole (VRZ). Methods: Powders were prepared by spray drying aqueous/alcohol solutions. Formulations were characterized in terms of particle size, morphology, thermal, moisture responses and aerosolization performance. Optimized powder was deposited onto an air-interface Calu-3 model to assess their uptake across Calu-3 lung epithelia. Optimized formulation was evaluated for stability (drug content and aerosol performance) for 3 months. Additionally, Calu-3 cell viability, lung bioavailability and tissue distribution of optimized formulation were evaluated. Results: Particle size and aerosol performance of dry powder containing 80% w/w VRZ and 20% w/w leucine was appropriate for inhalation therapy. Optimized formulation showed irregular morphology, crystalline nature, low moisture sensitivity and was stable for 3 months at room temperature. Leucine did not alter the transport kinetics of VRZ, as evaluated by air-interface Calu-3 model. Formulation was non-cytotoxic to pulmonary epithelial cells. Moreover, lung bioavailability and tissue distribution studies in murine model clearly showed that VRZ dry powder inhalable formulation has potential to enhance therapeutic efficacy at the pulmonary infection site whilst minimizing systemic exposure and related toxicity. Conclusion: This study supports the potential of inhaled dry powder VRZ for the treatment of fungal infections.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1114603
  • [Show abstract] [Hide abstract]
    ABSTRACT: Encapsulation of subunit antigens into particulate vaccine delivery systems is a promising strategy to enhance their immunogenicity. The most basic physical parameter of these particles, their size, has a profound effect on the immunogenicity of the vaccine. Interestingly, the optimal particle size varies depending on the desired type of immunological memory and the route of administration. In this editorial we draw attention to the effect of particle size on the resulting immune response and accentuate the importance of adequate particle sizing methods, within and beyond the intended size range of the delivery vehicle, to assess vaccine quality.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1121989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: The purpose of this study was to investigate if the conjugation of Anti-HER2-Affibody to cisplatin PEGylated liposome can efficiently enhance the therapeutic effectiveness of the targeted liposome. Methods: First, Affibody molecules were incubated with Mal-PEG2000-DSPE micelle to afford formation of a maleimide-mediated thioether coupling to the COOH-terminal cysteine of Affibody. Cisplatin-loaded liposomes composed of HSPC/ cholesterol/ mPEG2000-DSPE (56.5:38.5:5 molar ratio) (150 mM) were prepared and characterized by their physicochemical properties. Affibody-conjugated micelles were then transferred into preformed liposomes by means of post-insertion. The cytotoxicity and cellular uptake of Affibody-targeted (affisome) and non-targeted liposomes were tested in HER2(+) SK-BR-3, and the in vivo therapeutic activity was evaluated in TUBO breast cancer models. Results: Anti-HER2 affisome demonstrated a higher amount of platinum intracellularly, and affected HER2(+)-SK-BR-3 cell death was at lower concentrations compared to its liposome counterparts. Further, cisplatin-affisome showed greater therapeutic efficiency than non-targeted liposome in HER2(+)-TUBO models. Equally promising, the affisome-treated mice did extend the survival of animals by several days and even left one tumor-free survivor. Conclusions: Affibody-targeting endowed cisplatin liposomes with significantly enhanced, albeit modest, therapeutic activity in HER2-overexpressing tumor model, however, further values are yet to be determined to advance clinical translation of these targeted nanoparticulates.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1121987
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease (CVD) is the leading cause of mortality globally. Effective CVD preventive medications are available including statin, blood pressure-lowering and antiplatelet medications; however most people do not take these drugs long term. Fixed-dose combination pills ("polypills") have been shown, in several clinical trials, to improve adherence to these recommended medications, with corresponding improvements in risk factors such as blood pressure and LDL-cholesterol. In patients not taking all modalities of recommended CVD preventive therapies, polypill-based strategies could importantly contribute to global CVD control strategies. The largest benefits are seen in those who are under-treated at baseline, rather than those who are already taking the individual components separately: simplified step-up is more important than pill count reduction. Despite the potential benefits for patients and payers, only a few polypills are available due to market failure in the funding of research and development for affordable non-communicable disease medicines. Regulatory paradigms have focused on substitution indications among patients already taking component medications; however, this is the population that is likely to receive the least benefit from a polypill-based strategy. Greater health impact is likely if focus is given to patients who have indications for all polypill components, but currently do not receive the benefits of recommended medicines long term.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1111869
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: The purpose of the study was to develop a floating matrix tablet of Nicorandil using blends of hydrophilic cellulose and pH-independent acrylic polymer to improve the therapeutic effectiveness of the drug in cardiovascular disease. Methods: Nicorandil tablets were prepared by direct compression and evaluated for drug-excipients compatibility, in-vitro buoyancy and in-vivo γ-scintigraphy study. The optimized formulation (FT5) was also evaluated for stability study and the in-vivo absorption in rabbits to compare the pharmacokinetic parameters with commercially available immediate release tablet of Nicorandil. Results: DSC and FT-IR studies confirmed the absence of incompatibility. The in-vivo γ-scintigraphy studies revealed that the system remain float for a periods of 6 -7 h in stomach. Results of stability study showed that the formulation was stable at refrigerator (2-8°C) and at 25ºC/60% RH. In-vivo absorption study showed a significant difference (p < 0.05) in the pharmacokinetic parameters (AUC increased by 3 fold and MRT by 2.5 fold) as compared to the marketed formulation. Conclusion: Overall studies demonstrate that controlled release floating tablet of Nicorandil improved the pharmacokinetic parameters (AUC and MRT) in rabbit plasma which expected to enhance the therapeutic effectiveness and lowering in side effects potential of the drug in cardiovascular diseases.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1118047
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: According to the European Pharmacopoeia oromucosal films comprise mucoadhesive buccal films and orodispersible films. Both oral dosage forms receive considerable interest in the recent years as commercially available pharmaceutical products and as small scale personalized extemporaneous preparations. Areas covered: In this review technological issues such as viscosity of the casting liquid, mechanical properties of the film, upscaling and the stability of the casting solution and produced films will be discussed. Furthermore, patient related problems like appearance, mucosal irritation, taste, drug-load, safety and biopharmaceutics are described. Current knowledge and directions for solutions are summarized. Expert opinion: The viscosity of the casting solution is a key factor for producing suitable films. This parameter is amongst others dependent on the polymer and API (active-pharmaceutical-ingredient) and the further excipients used. For optimal patient compliance an acceptable taste and palatability are desirable. Safe and inert excipients should be used and appropriate packaging should be provided to produced films. Absorption through the oral mucosa will vary for each active compound, formulation and patient, which gives rise to pharmacokinetic questions. Finally, the European Pharmacopoeia needs to specify methods, requirement and definitions for oromucosal film preparations based on bio-relevant data.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1118048
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The skin, as the largest organ, is a better option for drug delivery in many diseases. However, most transdermal delivery is difficult due to the low permeability of therapeutics across the various skin layers. There have been many innovations in transdermal drug delivery to enhance the therapeutic efficacy of the drugs administered. Microneedles (MN), micron sized needles, are of great interest to scientists as a novel therapeutic vehicle via transdermal routes, especially for vaccines, drugs, small molecules, etc. Areas covered: This review covers new insights into different types of MNs such as solid, hollow, coated and dissolving MNs for selected biomedical applications in detail. Specific focus has been given to coated and dissolving MNs for vaccine and drug delivery applications with recent developments in novel MNs covered. Expert opinion: This review explores the feasibility of innovative MNs used as a drug delivery carrier. Because most of the solid and hollow MNs have many limitations, it is difficult to achieve therapeutic efficacy. Therefore, many scientists are investigating functional modifications of MNs through covalent and non-covalent methods, especially for coated and dissolving MNs. The biomedical applications of MNs are growing and new exciting improvements could be achieved, thus resulting in better micro/nano technologies in the near future.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1115835
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Stimulative nanostructures play a crucial role in developing the smart nanomedicine for high therapeutic efficacy with minimum adverse effects. Herein, a near-infrared (NIR) light responsive nanohybrids pGO-CuS/ICG comprised of nanographene oxide (GO), copper sulfide (CuS) nanoparticles and photosensitizer indocyanine green (ICG) was fabricated to couple the photothermal property of CuS and photodynamic effect of ICG in one system in order to achieve the synergistic phototherapy. Methods: pGO-CuS/ICG was constructed by self-assembling ICG on pGO-CuS nanostructure. Its physicochemical, photothermal and photodynamic properties were studied by spectroscopic methods. The in vitro cellular uptake, cytotoxicity, the single/combined photothermal therapeutic (PTT) and photodynamic therapeutic (PDT) effects were investigated with biological techniques. Results: pGO-CuS/ICG exhibited high efficacy of photothermal conversation and singlet oxygen generation under NIR laser excitation. It entered into the target cancer cells probably via passive transmembrane pathway and exerted obvious PTT and PDT effect against the tumor cells upon irradiation with the respective 940 nm and 808 nm lasers. Particularly, the tremendous synergistic efficacy of PDT and PTT had been demonstrated by tuning the NIR laser combined irradiation. Conclusions: This study promises the future applications of pGO-CuS/ICG as a NIR light activable theranostic nanodrug for deep-seated cancer noninvasive phototherapy.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1118049
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: There are several hurdles to oral insulin delivery (OID): mainly, enzymatic proteolysis, gastric degradation, and an absorption barrier. Researchers have been attempting to overcome these natural barriers through chitosan-based insulin formulations. Areas covered: In this paper, the authors review OID formulations to elucidate their techniques and evaluate their performance through a set of defined parameters and suggest overall outlooks and future directions. This review covers 86 articles and reveals that most oral insulin formulations were obtained through poly-electrolytic complexation or chemical modification techniques. The in-vitro results reported by the articles are mapped into a '30x70 performance window' to distinguish the best OID formulations. The review shows that most formulations were effective in addressing the gastric and enzymatic barriers but were not as effective in overcoming the absorption barrier of the gastrointestinal tract. Expert opinion: Oral insulin delivery has been a topic of immense research with most efforts dedicated to developing a formidable insulin formulation that overcomes gastrointestinal tract barriers. While most OID formulations perform better under experimental conditions, their performance in in-vivo studies is not as effective. Thus, to make oral insulin delivery a reality, special attention is needed toward improving the in-vivo insulin absorption through the gut.
    Expert Opinion on Drug Delivery 11/2015; DOI:10.1517/17425247.2016.1107543
  • [Show abstract] [Hide abstract]
    ABSTRACT: Refinement of micro- and nanofabrication in the semiconductor field has led to innovations in biomedical technologies. Nanotopography, in particular, shows great potential in facilitating drug delivery. The flexibility of fabrication techniques has created a diverse array of topographies that have been developed for drug delivery applications. Nanowires and nanostraws deliver drug cytosolically for in vitro and ex vivo applications. In vivo drug delivery is limited by the barrier function of the epithelium. Nanowires on microspheres increase adhesion and residence time for oral drug delivery, while also increasing permeability of the epithelium. Low aspect ratio nanocolumns increase paracellular permeability, and in conjunction with microneedles increase transdermal drug delivery of biologics in vivo. In summary, nanotopography is a versatile tool for drug delivery. It can deliver directly to cells or be used for in vivo delivery across epithelial barriers. This editorial highlights the application of nanotopography in the field of drug delivery.
    Expert Opinion on Drug Delivery 10/2015; DOI:10.1517/17425247.2015.1103734
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Intravesical therapy is a valuable option in the clinical management of urinary tract disorders such as interstitial cystitis/ painful bladder syndrome (IC/PBS) and refractory overactive bladder. This review will cover the latest advances in this field using polymer and liposomes as delivery platform for drugs, protein and nucleic acids. Areas covered: This review summarizes the significance of intravesical therapy for lower urinary tract disorders. The recent advancement of liposomes as a drug delivery platform for botulinum toxin, tacrolimus and small interfering RNA is discussed. The importance of polymers forming indwelling devices and hydrogels are also discussed, where all preparations improved efficacy parameters in rodent models. Clinical experience of treating IC/PBS with indwelling devices and liposomes are summarized and preclinical evidence about the downregulation of target gene expression in rodent bladder with liposomes complexed with siRNA is also reviewed. Expert opinion: There have been several advances in the field of intravesical therapy for improving clinical outcomes. One of the most promising research avenues is the repurposing of drugs, given previously by other routes of administration, such as tacrolimus. Intravesical therapy also opens up novel therapeutic targets with improved efficacy and safety for underactive bladder.
    Expert Opinion on Drug Delivery 10/2015; DOI:10.1517/17425247.2016.1100166
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the widespread availability of insulin pumps, continuous glucose sensors, and insulin analogs with rapid-acting pharmacokinetic profiles, most people with type 1 diabetes fail to meet recommended glycemic targets, rates of severe hypoglycemia remain unacceptably high, and the burden of care on patients and loved ones exacts an enormous psychosocial toll. The combination of continuous glucose monitoring with insulin delivery into an integrated automated system promises to improve diabetes control while at the same time reduce the burden of care. A wide variety of automated insulin delivery systems, ranging in scope from simple pump suspension to reduce hypoglycemia, to complex multiple hormone systems under separate regulation and delivery, have been studied in both controlled inpatient settings and more free-ranging outpatient environments. Preliminary findings have been positive, with most studies demonstrating reduction in overall glucose levels, increased time-in-target range, and reductions in exposure to hypoglycemia. As these systems move closer to commercialization, the focus of ongoing efforts will need to address the continuing challenges of sensor accuracy and reliability, connectivity issues, and human factors considerations.
    Expert Opinion on Drug Delivery 09/2015; 12(10):1579-1582. DOI:10.1517/17425247.2015.1074174
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: A drug delivery system based on colloidal pegylated gold nanoparticles (PEGAuNPs) conjugated with the tyrosine kinase inhibitor afatinib was designed and tested for enhancing the drug activity against pancreatic and NSCLC cells. Methods: PEGAuNPs were synthesized and characterized physicochemically. Confocal imaging was performed to evaluate the nanoparticle (NP) internalization in cancer cells. For cell-cycle distribution analysis, conjugated NPs and afatinib alone were incubated with cells and alterations on the cell-cycle profile subsequently analyzed by total DNA staining. Cancer cell survival and growth inhibition following incubation with afatinib and PEGAuNPs-afatinib (concentrations between 0.007 and 0.500 µM afatinib) were evaluated. Results: A higher cellular uptake of PEGAuNPs was observed by cancer cells. Our data suggest an efficient conjugation of PEGAuNPs with the drug, enhancing the afatinib activity in comparison with afatinib alone. In fact, IC50 and GI50 results obtained show that the PEGAuNPs-afatinib conjugate is ca. 5 and 20 times more potent than afatinib alone in S2-013 and A549 cell lines, respectively. Conclusions: Conjugating PEGAuNPs with afatinib is a promising antitumor delivery system for cancer therapy as it improves drug efficacy, allowing a reduction in drug dose used and minimizing possible toxicity-related side effects.
    Expert Opinion on Drug Delivery 09/2015; DOI:10.1517/17425247.2015.1083973